Co-Diagnostics Inc
CODX
Company Profile
Business description
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
Contact
2401 S. Foothill Drive
Suite D
Salt Lake CityUT84109
USAT: +1 801 438-1036
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
115
Stocks News & Analysis
stocks
ASX gold miner under pressure to sell by activist investor
Activist investor presses gold miner on selling to larger players.
stocks
Ask the Analyst: Will Amcor lose its dividend aristocrat status?
When consistency becomes constraint.
stocks
Chart of the Week: We see opportunity in this beaten down industrial player
The market sees risks and are discounting the shares excessively.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,017.20 | 3.10 | -0.03% |
| CAC 40 | 8,150.42 | 58.67 | -0.71% |
| DAX 40 | 24,795.94 | 328.23 | -1.31% |
| Dow JONES (US) | 50,687.07 | 620.72 | -1.21% |
| FTSE 100 | 10,332.30 | 41.21 | -0.40% |
| HKSE | 25,633.21 | 405.11 | -1.56% |
| NASDAQ | 26,853.98 | 239.92 | -0.89% |
| Nikkei 225 | 68,402.13 | 1,667.89 | 2.50% |
| NZX 50 Index | 13,115.08 | 55.63 | -0.42% |
| S&P 500 | 7,553.68 | 56.10 | -0.74% |
| S&P/ASX 200 | 8,785.70 | 5.90 | 0.07% |
| SSE Composite Index | 4,083.97 | 8.87 | 0.22% |